Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 29 min ago
Peer-reviewedCC BY-NC-NDJournal of thoracic disease

Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer.

  • Robert Roskoski1
  1. 1Department of Pharmacology, Blue Ridge Institute for Medical Research, Hendersonville, NC, USA.
Read full textPDFDOICite

Related

  1. Efficacy and safety of neoadjuvant targeted therapy in surgically treated patients with ALK-rearranged non-small cell lung cancer
    Yudong Liu, Li Fang, Zhongjing Jiang +3
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. 1180 Interim safety and efficacy results of Victoria-01: a phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors
    Radka Obermannova, Aung Naing, Hans Prenen +11
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study
    Jiajie Sun, Xinjing Li, Bingxue Wang +7
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
  5. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
    Arlene Siefker-Radtke, Andrea Necchi, Se Hoon Park +103
    Lancet OncologyPeer-reviewedLicence not stated171 citedSurgery & anaesthesiaHAL

Cite

BibTeXRIS
BibTeX
@article{roskoski2026final,
  title = {{Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer.}},
  author = {Robert Roskoski},
  journal = {Journal of thoracic disease},
  year = {2026},
  month = oct,
  doi = {10.21037/jtd-2026-2402},
  url = {https://europepmc.org/article/MED/42996935},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer.
AU  - Robert Roskoski
PY  - 2026
DA  - 2026/10/15
JO  - Journal of thoracic disease
DO  - 10.21037/jtd-2026-2402
UR  - https://europepmc.org/article/MED/42996935
SN  - 2072-1439
SN  - 2077-6624
ER  -